Cantor Fitzgerald’s Bionano Genomics BNGO Stock Holding History

Cantor Fitzgerald’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-83	Closed	-$687K	–	296
2023 Q3	$687K	Buy	83 +75	+938%	+$19.6K	0.02%	300
2023 Q2	$461K	Buy	+8	New	+$3.61K	0.01%	381

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cantor Fitzgerald's BNGO Position: Q1 2024 in Review

Cantor Fitzgerald sold out of Bionano Genomics (BNGO) in Q1 2024, closing a stake of 917 shares — an estimated $750K sold.

Cantor Fitzgerald first reported a position in BNGO in Q2 2023 and held it in 3 quarters. The position peaked at $750K in Q4 2023. 55 funds tracked by Wall St. Rank hold BNGO as of Q1 2024.

Cantor Fitzgerald reported no remaining Bionano Genomics position as of Q1 2024 after selling out during the quarter.
Cantor Fitzgerald sold 917 Bionano Genomics shares in Q1 2024, an estimated $750K.
Cantor Fitzgerald first reported a position in Bionano Genomics in Q2 2023 and held it in 3 quarters.
Cantor Fitzgerald's Bionano Genomics position peaked at $750K in Q4 2023.
55 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2024.

Based on Cantor Fitzgerald's 13F filing for Q1 2024, filed 15 May 2024.